The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma

Journal of Immunology

Volumn 190, Issue 8, 2013, Pages 3905-3915

  Makino, Katsunari ^a   Jinnin, Masatoshi ^a   Hirano, Ayaka ^a   Yamane, Keitaro ^a   Eto, Mitsuhiko ^a   Kusano, Takamitsu ^a   Honda, Noritoshi ^a   Kajihara, Ikko ^a   Makino, Takamitsu ^a   Sakai, Keisuke ^a   Masuguchi, Shinichi ^a   Fukushima, Satoshi ^a   Ihn, Hironobu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; MICRORNA; MICRORNA LET 7A; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; IN VITRO STUDY; IN VIVO STUDY; KELOID; LOCALIZED SCLEROSIS; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; SCLEROSIS; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

COLLAGEN TYPE I; DOWN-REGULATION; HUMANS; MICRORNAS; SCLERODERMA, SYSTEMIC; SKIN; UP-REGULATION;

EID: 84875979967     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200822     Document Type: Article

References (53)

1. Fett, N., and V. P. Werth. 2011. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J. Am. Acad. Dermatol. 64: 217-228, quiz 229-230.
2. Fett, N., and V. P. Werth. 2011. Update on morphea: part II. Outcome measures and treatment. J. Am. Acad. Dermatol. 64: 231-242, quiz 243-244.
3. Jablonska, S., and G. Rodnan. 1979. Localized forms of scleroderma. Clin. Rheum. Dis. 5: 215-241.
4. Higley, H., K. Persichitte, S. Chu, W. Waegell, R. Vancheeswaran, and C. Black. 1994. Immunocytochemical localization and serologic detection of transforming growth factor β1: association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum. 37: 278-288.
5. Kubo, M., H. Ihn, K. Yamane, and K. Tamaki. 2001. Up-regulated expression of transforming growth factor b receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum. 44: 731-734.
6. Asano, Y., H. Ihn, K. Yamane, M. Jinnin, Y. Mimura, and K. Tamaki. 2004. Phosphatidylinositol 3-kinase is involved in a2(I) collagen gene expression in normal and scleroderma fibroblasts. J. Immunol. 172: 7123-7135.
7. Asano, Y., H. Ihn, K. Yamane, M. Kubo, and K. Tamaki. 2004. Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J. Clin. Invest. 113: 253-264.
8. Asano, Y., H. Ihn, K. Yamane, M. Jinnin, Y. Mimura, and K. Tamaki. 2005. Differential effects of the immunosuppressant FK-506 on human α2(I) collagen gene expression and transforming growth factor b signaling in normal and scleroderma fibroblasts. Arthritis Rheum. 52: 1237-1247.
9. Kahaleh, B. 1993. Immunologic aspects of scleroderma. Curr. Opin. Rheumatol. 5: 760-765.
10. Takehara, K., and S. Sato. 2005. Localized scleroderma is an autoimmune disorder. Rheumatology 44: 274-279.
11. 5 integrin in the establishment of autocrine TGF-β signaling in dermal fibroblasts derived from localized scleroderma. J. Invest. Dermatol. 126: 1761-1769.
12. Ala-Kokko, L., A. Rintala, and E. R. Savolainen. 1987. Collagen gene expression in keloids: analysis of collagen metabolism and type I, III, IV, and V procollagen mRNAs in keloid tissue and keloid fibroblast cultures. J. Invest. Dermatol. 89: 238-244.
13. Smith, J. C., B. E. Boone, S. R. Opalenik, S. M. Williams, and S. B. Russell. 2008. Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways. J. Invest. Dermatol. 128: 1298-1310.
14. Fujiwara, M., Y. Muragaki, and A. Ooshima. 2005. Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration. Br. J. Dermatol. 153: 295-300.
15. Syed, F., E. Ahmadi, S. A. Iqbal, S. Singh, D. A. McGrouther, and A. Bayat. 2011. Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralesional and extralesional sites: clinical implications for lesional site-directed therapy. Br. J. Dermatol. 164: 83-96.
16. Davidson-Moncada, J., F. N. Papavasiliou, and W. Tam. 2010. MicroRNAs of the immune system: roles in inflammation and cancer. Ann. N. Y. Acad. Sci. 1183: 183-194.
17. Furer, V., J. D. Greenberg, M. Attur, S. B. Abramson, and M. H. Pillinger. 2010. The role of microRNA in rheumatoid arthritis and other autoimmune diseases. Clin. Immunol. 136: 1-15.
18. Herrera, B. M., H. E. Lockstone, J. M. Taylor, M. Ria, A. Barrett, S. Collins, P. Kaisaki, K. Argoud, C. Fernandez, M. E. Travers, et al. 2010. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 53: 1099-1109.
19. Friedman, R. C., K. K. Farh, C. B. Burge, and D. P. Bartel. 2009. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19: 92-105.
20. LeRoy, E. C., C. Black, R. Fleischmajer, S. Jablonska, T. Krieg, T. A. Medsger, Jr., N. Rowell, and F. Wollheim. 1988. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15: 202-205.
21. Ihn, H., S. Sato, M. Fujimoto, K. Kikuchi, A. Igarashi, Y. Soma, K. Tamaki, and K. Takehara. 1996. Measurement of anticardiolipin antibodies by ELISA using b2-glycoprotein I (b2-GPI) in systemic sclerosis. Clin. Exp. Immunol. 105: 475-479.
22. Sato, S., M. Fujimoto, H. Ihn, K. Kikuchi, and K. Takehara. 1994. Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. J. Am. Acad. Dermatol. 31: 567-571.
23. Falanga, V., T. A. Medsger, and M. Reichlin. 1985. High titers of antibodies to single-stranded DNA in linear scleroderma. Arch. Dermatol. 121: 345-347.
24. Ihn, H., E. C. LeRoy, and M. Trojanowska. 1997. Oncostatin M stimulates transcription of the human a2(I) collagen gene via the Sp1/Sp3-binding site. J. Biol. Chem. 272: 24666-24672.
25. Kroh, E. M., R. K. Parkin, P. S. Mitchell, and M. Tewari. 2010. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50: 298-301.
26. Zhang, Y., J. Guo, D. Li, B. Xiao, Y. Miao, Z. Jiang, and H. Zhuo. 2010. Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. Med. Oncol. 27: 685-689.
27. Ihn, H., S. Sato, M. Fujimoto, K. Kikuchi, and K. Takehara. 1996. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma. Br. J. Dermatol. 134: 843-847.
28. Ihn, H., N. Yazawa, M. Kubo, K. Yamane, S. Sato, M. Fujimoto, K. Kikuchi, Y. Soma, and K. Tamaki. 2000. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J. Rheumatol. 27: 698-702.
29. Martin, M. M., J. A. Buckenberger, J. Jiang, G. E. Malana, G. J. Nuovo, M. Chotani, D. S. Feldman, T. D. Schmittgen, and T. S. Elton. 2007. The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding. J. Biol. Chem. 282: 24262-24269.
30. Nuovo, G. J. 2008. In situ detection of precursor and mature microRNAs in paraffin embedded, formalin fixed tissues and cell preparations. Methods 44: 39-46.
31. Kim, S. J., J. Y. Shin, K. D. Lee, Y. K. Bae, K. W. Sung, S. J. Nam, and K. H. Chun. 2012. MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res. 14: R14.
32. Yang, Q., Z. Jie, H. Cao, A. R. Greenlee, C. Yang, F. Zou, and Y. Jiang. 2011. Low-level expression of let-7a in gastric cancer and its involvement in tumori-genesis by targeting RAB40C. Carcinogenesis 32: 713-722.
33. Yamamoto, T., S. Takagawa, I. Katayama, K. Yamazaki, Y. Hamazaki, H. Shinkai, and K. Nishioka. 1999. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J. Invest. Dermatol. 112: 456-462.
34. Tanaka, C., M. Fujimoto, Y. Hamaguchi, S. Sato, K. Takehara, and M. Hasegawa. 2010. Inducible costimulator ligand regulates bleomycin-induced lung and skin fibrosis in a mouse model independently of the inducible costimulator/inducible costimulator ligand pathway. Arthritis Rheum. 62: 1723-1732.
35. Kashiyama, K., N. Mitsutake, M. Matsuse, T. Ogi, V. A. Saenko, K. Ujifuku, A. Utani, A. Hirano, and S. Yamashita. 2012. miR-196a downregulation increases the expression of type I and III collagens in keloid fibroblasts. J. Invest. Dermatol. 132: 1597-1604.
36. Mauch, C., E. Kozlowska, B. Eckes, and T. Krieg. 1992. Altered regulation of collagen metabolism in scleroderma fibroblasts grown within three-dimensional collagen gels. Exp. Dermatol. 1: 185-190.
37. Lewis, B. P., C. B. Burge, and D. P. Bartel. 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
38. John, B., A. J. Enright, A. Aravin, T. Tuschl, C. Sander, and D. S. Marks. 2004. Human MicroRNA targets. PLoS Biol. 2: e363.
39. Kiriakidou, M., P. T. Nelson, A. Kouranov, P. Fitziev, C. Bouyioukos, Z. Mourelatos, and A. Hatzigeorgiou. 2004. A combined computational-experimental approach predicts human microRNA targets. Genes Dev. 18: 1165-1178.
40. Krek, A., D. Grün, M. N. Poy, R. Wolf, L. Rosenberg, E. J. Epstein, P. MacMenamin, I. da Piedade, K. C. Gunsalus, M. Stoffel, and N. Rajewsky. 2005. Combinatorial microRNA target predictions. Nat. Genet. 37: 495-500.
41. Long, J. M., and D. K. Lahiri. 2011. MicroRNA-101 downregulates Alzheimer's amyloid-b precursor protein levels in human cell cultures and is differentially expressed. Biochem. Biophys. Res. Commun. 404: 889-895.
42. Chen, X., Y. Ba, L. Ma, X. Cai, Y. Yin, K. Wang, J. Guo, Y. Zhang, J. Chen, X. Guo, et al. 2008. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18: 997-1006.
43. Mitchell, P. S., R. K. Parkin, E. M. Kroh, B. R. Fritz, S. K. Wyman, E. L. Pogosova-Agadjanyan, A. Peterson, J. Noteboom, K. C. O'Briant, A. Allen, et al. 2008. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 105: 10513-10518.
44. Hunter, M. P., N. Ismail, X. Zhang, B. D. Aguda, E. J. Lee, L. Yu, T. Xiao, J. Schafer, M. L. Lee, T. D. Schmittgen, et al. 2008. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3: e3694.
45. Valenti, R., V. Huber, M. Iero, P. Filipazzi, G. Parmiani, and L. Rivoltini. 2007. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 67: 2912-2915.
46. Chen, X., H. Liang, J. Zhang, K. Zen, and C. Y. Zhang. 2012. Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell 3: 28-37.
47. Valadi, H., K. Ekström, A. Bossios, M. Sjöstrand, J. J. Lee, and J. O. Lötvall. 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9: 654-659.
48. Uziel, Y., B. R. Krafchik, B. Feldman, E. D. Silverman, L. A. Rubin, and R. M. Laxer. 1994. Serum levels of soluble interleukin-2 receptor. A marker of disease activity in localized scleroderma. Arthritis Rheum. 37: 898-901.
49. Takehara, K., K. Kikuchi, Y. Soma, A. Igarashi, and Y. Ishibashi. 1990. Anti-single-stranded DNA antibody and muscle involvement in localized sclero-derma. Arch. Dermatol. 126: 1368.
50. Takeshita, F., L. Patrawala, M. Osaki, R. U. Takahashi, Y. Yamamoto, N. Kosaka, M. Kawamata, K. Kelnar, A. G. Bader, D. Brown, and T. Ochiya. 2010. Systemic delivery of synthetic microRNA-16 inhibits the growth of meta-static prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 18: 181-187.
51. Lu, T. X., J. Hartner, E. J. Lim, V. Fabry, M. K. Mingler, E. T. Cole, S. H. Orkin, B. J. Aronow, and M. E. Rothenberg. 2011. MicroRNA-21 limits in vivo immune response-mediated activation of the IL-12/IFN-γ pathway, Th1 polarization, and the severity of delayed-type hypersensitivity. J. Immunol. 187: 3362-3373.
52. Lanford, R. E., E. S. Hildebrandt-Eriksen, A. Petri, R. Persson, M. Lindow, M.E. Munk, S. Kauppinen, and H. Ørum. 2010. Therapeutic silencingofmicroRNA-122 in primates with chronic hepatitis C virus infection. Science 327: 198-201.
53. Nakasa, T., H. Shibuya, Y. Nagata, T. Niimoto, and M. Ochi. 2011. The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum. 63: 1582-1590.